Stryker (SYK) 10-Q 30 Oct 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2020shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-13149
Entity Registrant Name	STRYKER CORP
Entity Incorporation, State or Country Code	MI
Entity Tax Identification Number	38-1239739
Entity Address, Address Line One	2825 Airview Boulevard
Entity Address, City or Town	Kalamazoo,
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	49002
City Area Code	(269)
Local Phone Number	385-2600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	375,790,657
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000310764
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of each class	Common Stock, $.10 Par Value
Trading Symbol	SYK
Security Exchange Name	NYSE
Senior Unsecured Notes 1.125% due 2021
Document Information [Line Items]
Title of each class	1.125% Notes due 2023
Trading Symbol	SYK23
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.250% Due 2024
Document Information [Line Items]
Title of each class	0.250% Notes due 2024
Trading Symbol	SYK24A
Security Exchange Name	NYSE
Senior Unsecured Notes 2.125% due 2027
Document Information [Line Items]
Title of each class	2.125% Notes due 2027
Trading Symbol	SYK27
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.750% Due 2029
Document Information [Line Items]
Title of each class	0.750% Notes due 2029
Trading Symbol	SYK29
Security Exchange Name	NYSE
Senior Unsecured Notes 2.625% due 2030
Document Information [Line Items]
Title of each class	2.625% Notes due 2030
Trading Symbol	SYK30
Security Exchange Name	NYSE
Senior Unsecured Notes, 1.000% Due 2031
Document Information [Line Items]
Title of each class	1.000% Notes due 2031
Trading Symbol	SYK31
Security Exchange Name	NYSE
Senior Unsecured Notes Variable due 2020
Document Information [Line Items]
Title of each class	Floating Rate Notes due 2020
Trading Symbol	SYK20A
Security Exchange Name	NYSE

Consolidated Statements Of Earn

Consolidated Statements Of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net sales	$ 3,737	$ 3,587	$ 10,089	$ 10,753
Cost of sales	1,276	1,257	3,749	3,760
Gross profit	2,461	2,330	6,340	6,993
Research, development and engineering expenses	242	246	729	717
Selling, general and administrative expenses	1,244	1,291	3,799	3,976
Recall charges	2	49	(4)	179
Amortization of intangible assets	114	116	342	352
Total operating expenses	1,602	1,702	4,866	5,224
Operating income	859	628	1,474	1,769
Other income (expense), net	(79)	(47)	(191)	(143)
Earnings before income taxes	780	581	1,283	1,626
Income taxes	159	115	252	268
Net earnings	$ 621	$ 466	$ 1,031	$ 1,358
Net earnings per share of common stock:
Basic	$ 1.66	$ 1.24	$ 2.75	$ 3.63
Diluted	$ 1.63	$ 1.23	$ 2.71	$ 3.58
Weighted-average shares outstanding (in millions):
Basic	375.7	374.2	375.3	373.8
Effect of dilutive employee stock compensation	4.5	6.1	4.7	6
Diluted	380.2	380.3	380	379.8
Cash dividends declared per share of common stock (in dollars per share)	$ 0.575	$ 0.52	$ 1.725	$ 1.56

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 621	$ 466	$ 1,031	$ 1,358
Other comprehensive income (loss), net of tax:
Marketable securities	0	0	0	1
Pension plans	(6)	13	(14)	2
Unrealized gains (losses) on designated hedges	(2)	(15)	(58)	(28)
Financial statement translation	(194)	79	(239)	103
Total other comprehensive income (loss), net of tax	(202)	77	(311)	78
Comprehensive income	$ 419	$ 543	$ 720	$ 1,436

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 7,083	$ 4,337
Marketable securities	78	88
Accounts receivable, less allowance of $125 ($88 in 2019)	2,426	2,893
Inventories:
Materials and supplies	751	677
Work in process	174	178
Finished goods	2,534	2,427
Total inventories	3,459	3,282
Prepaid expenses and other current assets	499	760
Total current assets	13,545	11,360
Property, plant and equipment:
Land, buildings and improvements	1,443	1,263
Machinery and equipment	3,396	3,451
Total property, plant and equipment	4,839	4,714
Less accumulated depreciation	2,310	2,147
Property, plant and equipment, net	2,529	2,567
Goodwill	9,128	9,069
Other intangibles, net	3,917	4,227
Noncurrent deferred income tax assets	1,627	1,575
Other noncurrent assets	1,540	1,369
Total assets	32,286	30,167
Current liabilities
Accounts payable	647	675
Accrued compensation	680	955
Income taxes	261	171
Dividends payable	216	213
Accrued expenses and other liabilities	1,766	1,527
Current maturities of debt	1,119	859
Total current liabilities	4,689	4,400
Long-term debt, excluding current maturities	12,008	10,231
Income taxes	999	1,068
Other noncurrent liabilities	1,604	1,661
Total liabilities	19,300	17,360
Shareholders' equity
Common stock, $0.10 par value	38	37
Additional paid-in capital	1,736	1,628
Retained earnings	12,129	11,748
Accumulated other comprehensive loss	(917)	(606)
Total shareholders' equity	12,986	12,807
Total liabilities and shareholders' equity	$ 32,286	$ 30,167

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 125	$ 88
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Total Stryker shareholders' equity	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Non-controlling interest
Beginning balance at Dec. 31, 2018			$ 37	$ 1,559	$ 10,765	$ (631)
Beginning balance (in shares) at Dec. 31, 2018			374.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans				(53)
Issuance of common stock under stock option and benefit plans (in shares)			1.9
Repurchase of common stock				(8)	(299)
Repurchase of common stock (in shares)			(1.9)
Share-based compensation				95
Net earnings	$ 1,358				1,358
Cash dividends declared					(586)
Other comprehensive income (loss)	78					78
Ending balance at Sep. 30, 2019	12,315	$ 12,315	$ 37	1,593	11,238	(553)	$ 0
Ending balance (in shares) at Sep. 30, 2019			374.4
Beginning balance at Jun. 30, 2019			$ 37	1,569	10,967	(630)
Beginning balance (in shares) at Jun. 30, 2019			374.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans				(8)
Issuance of common stock under stock option and benefit plans (in shares)			0.3
Repurchase of common stock (in shares)			0
Share-based compensation				32
Net earnings	466				466
Cash dividends declared					(195)
Other comprehensive income (loss)	77					77
Ending balance at Sep. 30, 2019	12,315	12,315	$ 37	1,593	11,238	(553)	0
Ending balance (in shares) at Sep. 30, 2019			374.4
Beginning balance at Dec. 31, 2019	12,807		$ 37	1,628	11,748	(606)
Beginning balance (in shares) at Dec. 31, 2019			374.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans			$ 1	(7)
Issuance of common stock under stock option and benefit plans (in shares)			1.3
Repurchase of common stock (in shares)			0
Share-based compensation				115
Net earnings	1,031				1,031
Cash dividends declared					(650)
Other comprehensive income (loss)	(311)					(311)
Ending balance at Sep. 30, 2020	12,986	12,986	$ 38	1,736	12,129	(917)	0
Ending balance (in shares) at Sep. 30, 2020			375.8
Beginning balance at Jun. 30, 2020			$ 38	1,706	11,725	(715)
Beginning balance (in shares) at Jun. 30, 2020			375.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans			$ 0	1
Issuance of common stock under stock option and benefit plans (in shares)			0.2
Repurchase of common stock (in shares)			0
Share-based compensation				29
Net earnings	621				621
Cash dividends declared					(217)
Other comprehensive income (loss)	(202)					(202)
Ending balance at Sep. 30, 2020	$ 12,986	$ 12,986	$ 38	$ 1,736	$ 12,129	$ (917)	$ 0
Ending balance (in shares) at Sep. 30, 2020			375.8

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net earnings	$ 1,031	$ 1,358
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	247	231
Amortization of intangible assets	342	352
Asset impairments	161	2
Share-based compensation	115	95
Recall charges	(4)	179
Sale of inventory stepped-up to fair value at acquisition	9	55
Changes in operating assets and liabilities:
Accounts receivable	467	(124)
Inventories	(154)	(414)
Accounts payable	(26)	37
Accrued expenses and other liabilities	(184)	64
Recall-related payments	(13)	(172)
Income taxes	5	(94)
Other, net	44	(113)
Net cash provided by operating activities	2,040	1,456
Investing activities
Acquisitions, net of cash acquired	(26)	(281)
Purchases of marketable securities	(34)	(57)
Proceeds from sales of marketable securities	44	52
Purchases of property, plant and equipment	(322)	(450)
Other investing, net	(11)	0
Net cash used in investing activities	(349)	(736)
Financing activities
Proceeds (payments) on short-term borrowings, net	3	(7)
Proceeds from issuance of long-term debt	2,293	0
Payments on long-term debt	(500)	(1,341)
Dividends paid	(647)	(585)
Repurchases of common stock	0	(307)
Cash paid for taxes from withheld shares	(79)	(130)
Other financing, net	(24)	10
Net cash provided by (used in) financing activities	1,046	(2,360)
Effect of exchange rate changes on cash and cash equivalents	9	(28)
Change in cash and cash equivalents	2,746	(1,668)
Cash and cash equivalents at beginning of period	4,337	3,616
Cash and cash equivalents at end of period	$ 7,083	$ 1,948

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION General Information Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," us" or "our") on September 30, 2020 and the results of operations for the three and nine months 2020. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2019. Certain prior year amounts have been reclassified to conform with current year presentation of segment results. New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. Accounting Pronouncements Recently Adopted On January 1, 2020 we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses for accounts receivables, loans and other financial instruments. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2020
Revenue Recognition [Abstract]
Revenue Recognition	REVENUE RECOGNITION Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2019. We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Net Sales by Product Line Three Months Nine Months 2020 2019 2020 2019 Orthopaedics: Knees $ 435 $ 426 $ 1,108 $ 1,305 Hips 334 332 866 1,011 Trauma and Extremities 430 407 1,152 1,197 Other 118 97 307 272 $ 1,317 $ 1,262 $ 3,433 $ 3,785 MedSurg: Instruments $ 467 $ 452 $ 1,308 $ 1,417 Endoscopy 467 474 1,238 1,424 Medical 600 554 1,819 1,627 Sustainability 66 72 181 212 $ 1,600 $ 1,552 $ 4,546 $ 4,680 Neurotechnology and Spine: Neurotechnology $ 518 $ 490 $ 1,370 $ 1,443 Spine 302 283 740 845 $ 820 $ 773 $ 2,110 $ 2,288 Total $ 3,737 $ 3,587 $ 10,089 $ 10,753 Net Sales by Geography Three Months 2020 Three Months 2019 United States International United States International Orthopaedics: Knees $ 332 $ 103 $ 318 $ 108 Hips 223 111 211 121 Trauma and Extremities 285 145 262 145 Other 97 21 81 16 $ 937 $ 380 $ 872 $ 390 MedSurg: Instruments $ 369 $ 98 $ 357 $ 95 Endoscopy 380 87 377 97 Medical 455 145 442 112 Sustainability 65 1 71 1 $ 1,269 $ 331 $ 1,247 $ 305 Neurotechnology and Spine: Neurotechnology $ 323 $ 195 $ 316 $ 174 Spine 219 83 209 74 $ 542 $ 278 $ 525 $ 248 Total $ 2,748 $ 989 $ 2,644 $ 943 Net Sales by Geography Nine Months 2020 Nine Months 2019 United States International United States International Orthopaedics: Knees $ 833 $ 275 $ 962 $ 343 Hips 564 302 643 368 Trauma and Extremities 753 399 768 429 Other 262 45 223 49 $ 2,412 $ 1,021 $ 2,596 $ 1,189 MedSurg: Instruments $ 1,028 $ 280 $ 1,121 $ 296 Endoscopy 997 241 1,136 288 Medical 1,363 456 1,288 339 Sustainability 179 2 210 2 $ 3,567 $ 979 $ 3,755 $ 925 Neurotechnology and Spine: Neurotechnology $ 835 $ 535 $ 929 $ 514 Spine 543 197 638 207 $ 1,378 $ 732 $ 1,567 $ 721 Total $ 7,357 $ 2,732 $ 7,918 $ 2,835 Contract Assets and Liabilities On September 30, 2020 there were no contract assets recorded on our Consolidated Balance Sheets.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income (AOCI)	9 Months Ended
	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive (Loss) Income (AOCI)	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI) Three Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (187) $ (9) $ (516) $ (715) OCI — (11) 2 (248) (257) Income taxes — 3 (1) 59 61 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (7) (6) Income taxes — — 1 2 3 Net OCI $ — $ (6) $ (2) $ (194) $ (202) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Three Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (148) $ 37 $ (516) $ (630) OCI — 11 (18) 116 109 Income taxes — 1 10 (32) (21) Reclassifications to: Cost of sales — — (2) — (2) Other (income) expense — 1 — (7) (6) Income taxes — — (5) 2 (3) Net OCI $ — $ 13 $ (15) $ 79 $ 77 Ending $ (3) $ (135) $ 22 $ (437) $ (553) Nine Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (179) $ 47 $ (471) $ (606) OCI — (25) (70) (285) (380) Income taxes — 5 18 61 84 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 8 (4) (20) (16) Income taxes — (2) 1 5 4 Net OCI $ — $ (14) $ (58) $ (239) $ (311) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Nine Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (4) $ (137) $ 50 $ (540) $ (631) OCI 1 (5) (34) 144 106 Income taxes — 4 18 (36) (14) Reclassifications to: Cost of sales — — (4) — (4) Other (income) expense — 4 — (7) (3) Income taxes — (1) (8) 2 (7) Net OCI $ 1 $ 2 $ (28) $ 103 $ 78 Ending $ (3) $ (135) $ 22 $ (437) $ (553)

Derivative Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTSWe use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2019. Foreign Currency Hedges September 2020 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 824 $ 1,169 $ 5,619 $ 7,612 Maximum term in days 1372 Fair value: Other current assets $ 10 $ — $ 13 $ 23 Other noncurrent assets 1 43 — 44 Other current liabilities (6) — (97) (103) Other noncurrent liabilities (2) — — (2) Total fair value $ 3 $ 43 $ (84) $ (38) December 2019 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 801 $ 1,113 $ 6,174 $ 8,088 Maximum term in days 1646 Fair value: Other current assets $ 5 $ — $ 180 $ 185 Other noncurrent assets 1 40 — 41 Other current liabilities (10) — (11) (21) Other noncurrent liabilities (2) — — (2) Total fair value $ (6) $ 40 $ 169 $ 203 In December 2019 and November 2018 we designated the issuance of €2,400 and €2,250 of senior unsecured notes as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries. On September 30, 2020 the total after tax gain (loss) amount in AOCI related to these designated net investment hedges was ($179). In July 2019 we entered into €1.0 billion in certain forward currency contracts and designated these as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. Net Currency Exchange Rate Gains (Losses) Three Months Nine Months Derivative instrument Recorded in: 2020 2019 2020 2019 Cash Flow Cost of sales $ 3 $ 2 $ 3 $ 4 Net Investment Other income (expense), net 7 7 20 7 Non-Designated Other income (expense), net (3) (6) (12) (10) Total $ 7 $ 3 $ 11 $ 1 Pretax gains (losses) on derivatives designated as cash flow of $6 and net investment hedges of $27 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense) in earnings within 12 months as of September 30, 2020. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment. Interest Rate Hedges In conjunction with our offerings of senior unsecured notes in December 2019 and June 2020 we terminated cash flow hedges with gross notional amounts of €600 and $500 designated as forward starting interest rate swaps of our interest rates, the impact of which will be recognized over time within interest expense. Pretax gains recorded in AOCI related to closed interest rate hedges of $6 are expected to be reclassified to other income (expense) in earnings within 12 months of September 30, 2020. On September 30, 2020 we had interest rate swap agreements with notional amounts of $750 designated as forward starting interest rate swaps in anticipation of future debt issuances. Pretax losses of $66 were recorded in AOCI as of September 30, 2020. Upon the probable issuance of the debt, these amounts will be released to interest expense over the term of the debt. The cash flow effect of these hedges is recorded in cash flow from operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2019. There were no significant transfers into or out of any level in 2020. Assets Measured at Fair Value September December 2020 2019 Cash and cash equivalents $ 7,083 $ 4,337 Trading marketable securities 154 149 Level 1 - Assets $ 7,237 $ 4,486 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 37 $ 32 United States agency debt securities 6 2 United States Treasury debt securities 34 49 Certificates of deposit 1 5 Total available-for-sale marketable securities $ 78 $ 88 Foreign currency exchange forward contracts 67 226 Interest rate swap asset — 17 Level 2 - Assets $ 145 $ 331 Total assets measured at fair value $ 7,382 $ 4,817 Liabilities Measured at Fair Value September December 2020 2019 Deferred compensation arrangements $ 154 $ 149 Level 1 - Liabilities $ 154 $ 149 Foreign currency exchange forward contracts $ 105 $ 23 Interest rate swap liability 65 — Level 2 - Liabilities $ 170 $ 23 Contingent consideration: Beginning $ 306 $ 117 Additions 5 298 Change in estimate 6 (10) Settlements (30) (99) Ending $ 287 $ 306 Level 3 - Liabilities $ 287 $ 306 Total liabilities measured at fair value $ 611 $ 478 Fair Value of Available for Sale Securities by Maturity September 2020 December 2019 Due in one year or less $ 40 $ 50 Due after one year through three years $ 38 $ 38 On September 30, 2020 and December 31, 2019 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income recorded in other income (expense), net, was $19 and $36 in the three months and $84 and $109 in the nine months 2020 and 2019. Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the

Contingencies and Commitments

Contingencies and Commitments	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	CONTINGENCIES AND COMMITMENTS We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for product liability claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. Recall Matters In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against. In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential. We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. Based on the information that has been received, we have estimated the remaining range of probable loss related to these matters globally to be approximately $280 to $515. We have recorded charges to earnings representing the minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows. Leases September December 2020 2019 Right-of-use assets $ 401 $ 384 Lease liabilities, current $ 100 $ 86 Lease liabilities, non-current $ 310 $ 301 Other information Weighted-average remaining lease term 5.5 years 6.2 years Weighted-average discount rate 2.87 % 3.34 % Three Months Nine Months 2020 2019 2020 2019 Operating lease cost $ 27 34 94 102

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $26 and $446 in the nine months 2020 and 2019. In October 2019 we completed the acquisition of Mobius Imaging and Cardan Robotics for net cash consideration of $360 and future regulatory and commercial milestone payments of up to $130. Mobius Imaging is a leader in point-of-care imaging technology focused on integrating advanced imaging technologies into medical workflow. Cardan Robotics is working to develop innovative robotics and navigation technology systems for surgical and interventional radiology procedures. Mobius Imaging and Cardan Robotics (Mobius) are part of our Spine business within Neurotechnology and Spine. For income tax purposes the acquisition was treated as an asset purchase. Goodwill attributable to the acquisition is deductible for tax purposes. In March 2019 we completed the acquisition of OrthoSpace, Ltd. (OrthoSpace) for net cash consideration of $110 and future regulatory milestone payments of up to $110. OrthoSpace is a medical device company specializing in orthopaedic biodegradable technology for the treatment of irreparable rotator cuff tears. OrthoSpace is part of our Endoscopy business within MedSurg. Goodwill attributable to the acquisition is not deductible for tax purposes. In November 2019 we announced a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of approximately $5.4 billion (including convertible notes). Pursuant to the agreement, on December 13, 2019 our wholly owned subsidiary, Stryker B.V., commenced a tender offer to purchase all of the outstanding ordinary shares, par value €0.03 per share, of Wright at a price of $30.75 per share, without interest, but subject to any applicable withholding of taxes. We expect the acquisition to close in the fourth quarter of 2020, subject to the expiration of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of other required approvals and clearances under applicable antitrust laws and other customary conditions. Wright is a global medical device company focused on extremities and biologics. Following closing, we plan to integrate Wright into our Trauma and Extremities business within Orthopaedics. Purchase price allocations for our significant acquisitions are: Purchase Price Allocation of Acquired Net Assets 2019 Mobius OrthoSpace Tangible assets: Accounts receivable $ 3 $ 1 Inventory 6 1 Other assets 2 1 Contingent consideration (4) — Other liabilities (10) (29) Intangible assets: Customer relationship 7 — Developed technology and patents 59 120 In-process research and development 98 — Non-compete agreements 9 — Goodwill 303 114 Purchase price, net of cash acquired $ 473 $ 208 Weighted-average life of intangible assets 12 18 The purchase price allocation for Mobius is based on preliminary valuations, primarily related to intangible assets that are subject to change within the measurement period. The purchase price allocation for OrthoSpace was finalized in 2020. Estimated Amortization Expense Remainder of 2020 2021 2022 2023 2024 $ 115 $ 446 $ 436 $ 421 $ 390

Debt and Credit Facilities

Debt and Credit Facilities	9 Months Ended
	Sep. 30, 2020
Long-term Debt, Unclassified [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on September 30, 2020. Our commercial paper program allows us to have a maximum of $1,500 in commercial paper outstanding with maturities up to 397 days from the date of issuance. On September 30, 2020 there were no amounts outstanding under our commercial paper program. Summary of Total Debt September 2020 December 2019 Senior unsecured notes: Rate Due 4.375% January 15, 2020 $ — $ 500 Variable November 30, 2020 351 333 2.625% March 15, 2021 750 749 1.125% November 30, 2023 640 609 3.375% May 15, 2024 590 587 0.250% December 3, 2024 987 938 1.150% June 15, 2025 644 — 3.375% November 1, 2025 747 746 3.500% March 15, 2026 992 991 2.125% November 30, 2027 871 829 3.650% March 7, 2028 596 596 0.750% March 1, 2029 929 884 1.950% June 15, 2030 988 — 2.625% November 30, 2030 749 712 1.000% December 3, 2031 865 823 4.100% April 1, 2043 392 391 4.375% May 15, 2044 395 395 4.625% March 15, 2046 981 981 2.900% June 15, 2050 641 — Other 19 26 Total debt $ 13,127 $ 11,090 Less current maturities of debt 1,119 859 Total long-term debt $ 12,008 $ 10,231 September 2020 December 2019 Unamortized debt issuance costs $ 71 $ 58 Available secured borrowing capacity $ 2,904 $ 1,403 Fair value of senior unsecured notes $ 14,366 $ 11,910 The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy. In January 2020 we repaid $500 of senior unsecured notes with a coupon of 4.375% that were due on January 15, 2020. On April 30, 2020 we amended our primary credit facility. The principal change was to increase the leverage ratio financial covenant from 3.5:1 to 4.5:1 at the end of each fiscal quarter ending on or prior to June 30, 2021. On April 30, 2020 we entered into a credit agreement that provides for up to $1,500 of borrowings in United States Dollars pursuant to a 364-day revolving credit facility, which matures on April 29, 2021 and is available for working capital and general corporate purposes. In June 2020 we issued $650 of senior unsecured notes with a fixed interest rate of 1.150% due on June 15, 2025, $1,000 of senior unsecured notes with a fixed interest rate of 1.950% due on June 15, 2030 and $650 of senior unsecured notes with a fixed interest rate of 2.900% due on June 15, 2050. The 2025 and 2030 notes are subject to a special mandatory redemption feature in which we will be required to redeem the notes in whole at a price equal to 101% of the aggregate principal amount plus accrued and unpaid interest if we do not consummate the Wright tender offer on or before February 4, 2021.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax [Abstract]
Income Taxes	INCOME TAXES Our effective tax rates were 20.4% and 19.8% in the three months and 19.6% and 16.5% in the nine months 2020 and 2019. The changes in the effective tax rates were primarily due to a change in geographic profit mix in the three months and a favorable audit settlement recorded in 2019 in the nine months. In March 2020 the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law in the United States. We do not expect the provisions of the CARES Act to have a material impact on our annual effective tax rate or Consolidated Financial Statements in 2020.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION Three Months Nine Months 2020 2019 2020 2019 Orthopaedics $ 1,317 $ 1,262 $ 3,433 $ 3,785 MedSurg 1,600 1,552 4,546 4,680 Neurotechnology and Spine 820 773 2,110 2,288 Net sales $ 3,737 $ 3,587 $ 10,089 $ 10,753 Orthopaedics $ 472 $ 437 $ 1,027 $ 1,322 MedSurg 451 394 1,085 1,179 Neurotechnology and Spine 228 199 513 608 Segment operating income $ 1,151 $ 1,030 $ 2,625 $ 3,109 Items not allocated to segments: Corporate and other (104) (117) (371) (371) Acquisition and integration-related charges (29) (32) (85) (223) Amortization of intangible assets (114) (116) (342) (352) Restructuring-related and other charges (29) (48) (292) (146) Medical device regulations (14) (15) (60) (34) Recall-related matters (2) (49) 4 (179) Regulatory and legal matters — (25) (5) (35) Consolidated operating income $ 859 $ 628 $ 1,474 $ 1,769 There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2019.

Asset Impairments

Asset Impairments	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Asset Impairments	ASSET IMPAIRMENTSThe significant negative impact the COVID-19 pandemic has had on Stryker’s operations and financial results has led to the decision to suspend certain in-process investments resulting in charges of $189 to impair certain long-lived assets (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and product line and other exit costs in the second quarter of 2020. These charges were included in cost of sales and selling, general and administrative expenses.

Basis Of Presentation (Policies

Basis Of Presentation (Policies)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.
Accounting Pronouncements Recently Adopted	Accounting Pronouncements Recently Adopted On January 1, 2020 we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses for accounts receivables, loans and other financial instruments. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue Recognition [Abstract]
Schedule of Disaggregated Revenue	We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Net Sales by Product Line Three Months Nine Months 2020 2019 2020 2019 Orthopaedics: Knees $ 435 $ 426 $ 1,108 $ 1,305 Hips 334 332 866 1,011 Trauma and Extremities 430 407 1,152 1,197 Other 118 97 307 272 $ 1,317 $ 1,262 $ 3,433 $ 3,785 MedSurg: Instruments $ 467 $ 452 $ 1,308 $ 1,417 Endoscopy 467 474 1,238 1,424 Medical 600 554 1,819 1,627 Sustainability 66 72 181 212 $ 1,600 $ 1,552 $ 4,546 $ 4,680 Neurotechnology and Spine: Neurotechnology $ 518 $ 490 $ 1,370 $ 1,443 Spine 302 283 740 845 $ 820 $ 773 $ 2,110 $ 2,288 Total $ 3,737 $ 3,587 $ 10,089 $ 10,753 Net Sales by Geography Three Months 2020 Three Months 2019 United States International United States International Orthopaedics: Knees $ 332 $ 103 $ 318 $ 108 Hips 223 111 211 121 Trauma and Extremities 285 145 262 145 Other 97 21 81 16 $ 937 $ 380 $ 872 $ 390 MedSurg: Instruments $ 369 $ 98 $ 357 $ 95 Endoscopy 380 87 377 97 Medical 455 145 442 112 Sustainability 65 1 71 1 $ 1,269 $ 331 $ 1,247 $ 305 Neurotechnology and Spine: Neurotechnology $ 323 $ 195 $ 316 $ 174 Spine 219 83 209 74 $ 542 $ 278 $ 525 $ 248 Total $ 2,748 $ 989 $ 2,644 $ 943 Net Sales by Geography Nine Months 2020 Nine Months 2019 United States International United States International Orthopaedics: Knees $ 833 $ 275 $ 962 $ 343 Hips 564 302 643 368 Trauma and Extremities 753 399 768 429 Other 262 45 223 49 $ 2,412 $ 1,021 $ 2,596 $ 1,189 MedSurg: Instruments $ 1,028 $ 280 $ 1,121 $ 296 Endoscopy 997 241 1,136 288 Medical 1,363 456 1,288 339 Sustainability 179 2 210 2 $ 3,567 $ 979 $ 3,755 $ 925 Neurotechnology and Spine: Neurotechnology $ 835 $ 535 $ 929 $ 514 Spine 543 197 638 207 $ 1,378 $ 732 $ 1,567 $ 721 Total $ 7,357 $ 2,732 $ 7,918 $ 2,835

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)	9 Months Ended
	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Three Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (187) $ (9) $ (516) $ (715) OCI — (11) 2 (248) (257) Income taxes — 3 (1) 59 61 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (7) (6) Income taxes — — 1 2 3 Net OCI $ — $ (6) $ (2) $ (194) $ (202) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Three Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (148) $ 37 $ (516) $ (630) OCI — 11 (18) 116 109 Income taxes — 1 10 (32) (21) Reclassifications to: Cost of sales — — (2) — (2) Other (income) expense — 1 — (7) (6) Income taxes — — (5) 2 (3) Net OCI $ — $ 13 $ (15) $ 79 $ 77 Ending $ (3) $ (135) $ 22 $ (437) $ (553) Nine Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (179) $ 47 $ (471) $ (606) OCI — (25) (70) (285) (380) Income taxes — 5 18 61 84 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 8 (4) (20) (16) Income taxes — (2) 1 5 4 Net OCI $ — $ (14) $ (58) $ (239) $ (311) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Nine Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (4) $ (137) $ 50 $ (540) $ (631) OCI 1 (5) (34) 144 106 Income taxes — 4 18 (36) (14) Reclassifications to: Cost of sales — — (4) — (4) Other (income) expense — 4 — (7) (3) Income taxes — (1) (8) 2 (7) Net OCI $ 1 $ 2 $ (28) $ 103 $ 78 Ending $ (3) $ (135) $ 22 $ (437) $ (553)
Reclassification out of Accumulated Other Comprehensive Income	Three Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (187) $ (9) $ (516) $ (715) OCI — (11) 2 (248) (257) Income taxes — 3 (1) 59 61 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 2 (1) (7) (6) Income taxes — — 1 2 3 Net OCI $ — $ (6) $ (2) $ (194) $ (202) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Three Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (148) $ 37 $ (516) $ (630) OCI — 11 (18) 116 109 Income taxes — 1 10 (32) (21) Reclassifications to: Cost of sales — — (2) — (2) Other (income) expense — 1 — (7) (6) Income taxes — — (5) 2 (3) Net OCI $ — $ 13 $ (15) $ 79 $ 77 Ending $ (3) $ (135) $ 22 $ (437) $ (553) Nine Months 2020 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (3) $ (179) $ 47 $ (471) $ (606) OCI — (25) (70) (285) (380) Income taxes — 5 18 61 84 Reclassifications to: Cost of sales — — (3) — (3) Other (income) expense — 8 (4) (20) (16) Income taxes — (2) 1 5 4 Net OCI $ — $ (14) $ (58) $ (239) $ (311) Ending $ (3) $ (193) $ (11) $ (710) $ (917) Nine Months 2019 Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ (4) $ (137) $ 50 $ (540) $ (631) OCI 1 (5) (34) 144 106 Income taxes — 4 18 (36) (14) Reclassifications to: Cost of sales — — (4) — (4) Other (income) expense — 4 — (7) (3) Income taxes — (1) (8) 2 (7) Net OCI $ 1 $ 2 $ (28) $ 103 $ 78 Ending $ (3) $ (135) $ 22 $ (437) $ (553)

Derivative Instruments (Tables)

Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	September 2020 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 824 $ 1,169 $ 5,619 $ 7,612 Maximum term in days 1372 Fair value: Other current assets $ 10 $ — $ 13 $ 23 Other noncurrent assets 1 43 — 44 Other current liabilities (6) — (97) (103) Other noncurrent liabilities (2) — — (2) Total fair value $ 3 $ 43 $ (84) $ (38) December 2019 Cash Flow Net Investment Non-Designated Total Gross notional amount $ 801 $ 1,113 $ 6,174 $ 8,088 Maximum term in days 1646 Fair value: Other current assets $ 5 $ — $ 180 $ 185 Other noncurrent assets 1 40 — 41 Other current liabilities (10) — (11) (21) Other noncurrent liabilities (2) — — (2) Total fair value $ (6) $ 40 $ 169 $ 203
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	Three Months Nine Months Derivative instrument Recorded in: 2020 2019 2020 2019 Cash Flow Cost of sales $ 3 $ 2 $ 3 $ 4 Net Investment Other income (expense), net 7 7 20 7 Non-Designated Other income (expense), net (3) (6) (12) (10) Total $ 7 $ 3 $ 11 $ 1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets Measured at Fair Value September December 2020 2019 Cash and cash equivalents $ 7,083 $ 4,337 Trading marketable securities 154 149 Level 1 - Assets $ 7,237 $ 4,486 Available-for-sale marketable securities: Corporate and asset-backed debt securities $ 37 $ 32 United States agency debt securities 6 2 United States Treasury debt securities 34 49 Certificates of deposit 1 5 Total available-for-sale marketable securities $ 78 $ 88 Foreign currency exchange forward contracts 67 226 Interest rate swap asset — 17 Level 2 - Assets $ 145 $ 331 Total assets measured at fair value $ 7,382 $ 4,817 Liabilities Measured at Fair Value September December 2020 2019 Deferred compensation arrangements $ 154 $ 149 Level 1 - Liabilities $ 154 $ 149 Foreign currency exchange forward contracts $ 105 $ 23 Interest rate swap liability 65 — Level 2 - Liabilities $ 170 $ 23 Contingent consideration: Beginning $ 306 $ 117 Additions 5 298 Change in estimate 6 (10) Settlements (30) (99) Ending $ 287 $ 306 Level 3 - Liabilities $ 287 $ 306 Total liabilities measured at fair value $ 611 $ 478
Investments Classified by Contractual Maturity Date	Fair Value of Available for Sale Securities by Maturity September 2020 December 2019 Due in one year or less $ 40 $ 50 Due after one year through three years $ 38 $ 38

Contingencies and Commitments (

Contingencies and Commitments (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease, Cost	Leases September December 2020 2019 Right-of-use assets $ 401 $ 384 Lease liabilities, current $ 100 $ 86 Lease liabilities, non-current $ 310 $ 301 Other information Weighted-average remaining lease term 5.5 years 6.2 years Weighted-average discount rate 2.87 % 3.34 %

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	Purchase Price Allocation of Acquired Net Assets 2019 Mobius OrthoSpace Tangible assets: Accounts receivable $ 3 $ 1 Inventory 6 1 Other assets 2 1 Contingent consideration (4) — Other liabilities (10) (29) Intangible assets: Customer relationship 7 — Developed technology and patents 59 120 In-process research and development 98 — Non-compete agreements 9 — Goodwill 303 114 Purchase price, net of cash acquired $ 473 $ 208 Weighted-average life of intangible assets 12 18
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated Amortization Expense Remainder of 2020 2021 2022 2023 2024 $ 115 $ 446 $ 436 $ 421 $ 390

Debt and Credit Facilities (Tab

Debt and Credit Facilities (Tables)	9 Months Ended
	Sep. 30, 2020
Long-term Debt, Unclassified [Abstract]
Schedule of Long-term Debt Instruments	Summary of Total Debt September 2020 December 2019 Senior unsecured notes: Rate Due 4.375% January 15, 2020 $ — $ 500 Variable November 30, 2020 351 333 2.625% March 15, 2021 750 749 1.125% November 30, 2023 640 609 3.375% May 15, 2024 590 587 0.250% December 3, 2024 987 938 1.150% June 15, 2025 644 — 3.375% November 1, 2025 747 746 3.500% March 15, 2026 992 991 2.125% November 30, 2027 871 829 3.650% March 7, 2028 596 596 0.750% March 1, 2029 929 884 1.950% June 15, 2030 988 — 2.625% November 30, 2030 749 712 1.000% December 3, 2031 865 823 4.100% April 1, 2043 392 391 4.375% May 15, 2044 395 395 4.625% March 15, 2046 981 981 2.900% June 15, 2050 641 — Other 19 26 Total debt $ 13,127 $ 11,090 Less current maturities of debt 1,119 859 Total long-term debt $ 12,008 $ 10,231 September 2020 December 2019 Unamortized debt issuance costs $ 71 $ 58 Available secured borrowing capacity $ 2,904 $ 1,403 Fair value of senior unsecured notes $ 14,366 $ 11,910

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Sales and Other Financial Information by Business Segment	Three Months Nine Months 2020 2019 2020 2019 Orthopaedics $ 1,317 $ 1,262 $ 3,433 $ 3,785 MedSurg 1,600 1,552 4,546 4,680 Neurotechnology and Spine 820 773 2,110 2,288 Net sales $ 3,737 $ 3,587 $ 10,089 $ 10,753 Orthopaedics $ 472 $ 437 $ 1,027 $ 1,322 MedSurg 451 394 1,085 1,179 Neurotechnology and Spine 228 199 513 608 Segment operating income $ 1,151 $ 1,030 $ 2,625 $ 3,109 Items not allocated to segments: Corporate and other (104) (117) (371) (371) Acquisition and integration-related charges (29) (32) (85) (223) Amortization of intangible assets (114) (116) (342) (352) Restructuring-related and other charges (29) (48) (292) (146) Medical device regulations (14) (15) (60) (34) Recall-related matters (2) (49) 4 (179) Regulatory and legal matters — (25) (5) (35) Consolidated operating income $ 859 $ 628 $ 1,474 $ 1,769

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Revenue Recognition [Abstract]
Contract liabilities	$ 389	$ 313

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 3,737	$ 3,587	$ 10,089	$ 10,753
United States
Disaggregation of Revenue [Line Items]
Net sales	2,748	2,644	7,357	7,918
International
Disaggregation of Revenue [Line Items]
Net sales	989	943	2,732	2,835
Orthopaedics
Disaggregation of Revenue [Line Items]
Net sales	1,317	1,262	3,433	3,785
Orthopaedics | United States
Disaggregation of Revenue [Line Items]
Net sales	937	872	2,412	2,596
Orthopaedics | International
Disaggregation of Revenue [Line Items]
Net sales	380	390	1,021	1,189
Orthopaedics | Knees
Disaggregation of Revenue [Line Items]
Net sales	435	426	1,108	1,305
Orthopaedics | Knees | United States
Disaggregation of Revenue [Line Items]
Net sales	332	318	833	962
Orthopaedics | Knees | International
Disaggregation of Revenue [Line Items]
Net sales	103	108	275	343
Orthopaedics | Hips
Disaggregation of Revenue [Line Items]
Net sales	334	332	866	1,011
Orthopaedics | Hips | United States
Disaggregation of Revenue [Line Items]
Net sales	223	211	564	643
Orthopaedics | Hips | International
Disaggregation of Revenue [Line Items]
Net sales	111	121	302	368
Orthopaedics | Trauma and Extremities
Disaggregation of Revenue [Line Items]
Net sales	430	407	1,152	1,197
Orthopaedics | Trauma and Extremities | United States
Disaggregation of Revenue [Line Items]
Net sales	285	262	753	768
Orthopaedics | Trauma and Extremities | International
Disaggregation of Revenue [Line Items]
Net sales	145	145	399	429
Orthopaedics | Other
Disaggregation of Revenue [Line Items]
Net sales	118	97	307	272
Orthopaedics | Other | United States
Disaggregation of Revenue [Line Items]
Net sales	97	81	262	223
Orthopaedics | Other | International
Disaggregation of Revenue [Line Items]
Net sales	21	16	45	49
MedSurg
Disaggregation of Revenue [Line Items]
Net sales	1,600	1,552	4,546	4,680
MedSurg | United States
Disaggregation of Revenue [Line Items]
Net sales	1,269	1,247	3,567	3,755
MedSurg | International
Disaggregation of Revenue [Line Items]
Net sales	331	305	979	925
MedSurg | Instruments
Disaggregation of Revenue [Line Items]
Net sales	467	452	1,308	1,417
MedSurg | Instruments | United States
Disaggregation of Revenue [Line Items]
Net sales	369	357	1,028	1,121
MedSurg | Instruments | International
Disaggregation of Revenue [Line Items]
Net sales	98	95	280	296
MedSurg | Endoscopy
Disaggregation of Revenue [Line Items]
Net sales	467	474	1,238	1,424
MedSurg | Endoscopy | United States
Disaggregation of Revenue [Line Items]
Net sales	380	377	997	1,136
MedSurg | Endoscopy | International
Disaggregation of Revenue [Line Items]
Net sales	87	97	241	288
MedSurg | Medical
Disaggregation of Revenue [Line Items]
Net sales	600	554	1,819	1,627
MedSurg | Medical | United States
Disaggregation of Revenue [Line Items]
Net sales	455	442	1,363	1,288
MedSurg | Medical | International
Disaggregation of Revenue [Line Items]
Net sales	145	112	456	339
MedSurg | Sustainability
Disaggregation of Revenue [Line Items]
Net sales	66	72	181	212
MedSurg | Sustainability | United States
Disaggregation of Revenue [Line Items]
Net sales	65	71	179	210
MedSurg | Sustainability | International
Disaggregation of Revenue [Line Items]
Net sales	1	1	2	2
Neurotechnology and Spine
Disaggregation of Revenue [Line Items]
Net sales	820	773	2,110	2,288
Neurotechnology and Spine | United States
Disaggregation of Revenue [Line Items]
Net sales	542	525	1,378	1,567
Neurotechnology and Spine | International
Disaggregation of Revenue [Line Items]
Net sales	278	248	732	721
Neurotechnology and Spine | Neurotechnology
Disaggregation of Revenue [Line Items]
Net sales	518	490	1,370	1,443
Neurotechnology and Spine | Neurotechnology | United States
Disaggregation of Revenue [Line Items]
Net sales	323	316	835	929
Neurotechnology and Spine | Neurotechnology | International
Disaggregation of Revenue [Line Items]
Net sales	195	174	535	514
Neurotechnology and Spine | Spine
Disaggregation of Revenue [Line Items]
Net sales	302	283	740	845
Neurotechnology and Spine | Spine | United States
Disaggregation of Revenue [Line Items]
Net sales	219	209	543	638
Neurotechnology and Spine | Spine | International
Disaggregation of Revenue [Line Items]
Net sales	$ 83	$ 74	$ 197	$ 207

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income (AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	$ (715)	$ (630)	$ (606)	$ (631)
OCI	(257)	109	(380)	106
Income taxes	61	(21)	84	(14)
Cost of sales	1,276	1,257	3,749	3,760
Other (income) expense	(79)	(47)	(191)	(143)
Income taxes	(159)	(115)	(252)	(268)
Net OCI	(202)	77	(311)	78
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(917)	(553)	(917)	(553)
Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	(3)	(2)	(3)	(4)
Other (income) expense	(6)	(6)	(16)	(3)
Income taxes	3	(3)	4	(7)
Net OCI	(202)	77	(311)	78
Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(3)	(3)	(3)	(4)
OCI	0	0	0	1
Income taxes	0	0	0	0
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(3)	(3)	(3)	(3)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	0	0	0	0
Income taxes	0	0	0	0
Net OCI	0	0	0	1
Pension Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(187)	(148)	(179)	(137)
OCI	(11)	11	(25)	(5)
Income taxes	3	1	5	4
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(193)	(135)	(193)	(135)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	2	1	8	4
Income taxes	0	0	(2)	(1)
Net OCI	(6)	13	(14)	2
Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(9)	37	47	50
OCI	2	(18)	(70)	(34)
Income taxes	(1)	10	18	18
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(11)	22	(11)	22
Hedges | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	(3)	(2)	(3)	(4)
Other (income) expense	(1)	0	(4)	0
Income taxes	1	(5)	1	(8)
Net OCI	(2)	(15)	(58)	(28)
Financial Statement Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(516)	(516)	(471)	(540)
OCI	(248)	116	(285)	144
Income taxes	59	(32)	61	(36)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(710)	(437)	(710)	(437)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	0	0	0	0
Other (income) expense	(7)	(7)	(20)	(7)
Income taxes	2	2	5	2
Net OCI	$ (194)	$ 79	$ (239)	$ 103

Derivative Instruments (Forward

Derivative Instruments (Forward Currency Exchange Contracts) (Details) € in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Jul. 31, 2019USD ($)	Nov. 30, 2018EUR (€)
Foreign Exchange Contract
Derivative [Line Items]
Notional Amount		$ 7,612	$ 8,088
Maximum term in days	1646 days	1372 days
Derivative, Fair Value, Net		$ (38)	203
Foreign Exchange Contract | Other current assets
Derivative [Line Items]
Derivative assets		23	185
Foreign Exchange Contract | Other noncurrent assets
Derivative [Line Items]
Derivative assets		44	41
Foreign Exchange Contract | Other current liabilities
Derivative [Line Items]
Derivative liabilities		(103)	(21)
Foreign Exchange Contract | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities		(2)	(2)
Foreign Exchange Contract | Net Investment
Derivative [Line Items]
Notional Amount		824	1,113	€ 2,400	$ 1,000	€ 2,250
Derivative, Fair Value, Net		3	40
Foreign Exchange Contract | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets		10	0
Foreign Exchange Contract | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets		1	40
Foreign Exchange Contract | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities		(6)	0
Foreign Exchange Contract | Net Investment | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities		(2)	0
Foreign Exchange Contract | Non-Designated
Derivative [Line Items]
Notional Amount		5,619	6,174
Derivative, Fair Value, Net		(84)	169
Foreign Exchange Contract | Non-Designated | Other current assets
Derivative [Line Items]
Derivative assets		13	180
Foreign Exchange Contract | Non-Designated | Other noncurrent assets
Derivative [Line Items]
Derivative assets		0	0
Foreign Exchange Contract | Non-Designated | Other current liabilities
Derivative [Line Items]
Derivative liabilities		(97)	(11)
Foreign Exchange Contract | Non-Designated | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities		0	0
Cash Flow | Foreign Exchange Contract | Net Investment
Derivative [Line Items]
Notional Amount			801
Derivative, Fair Value, Net			(6)
Cash Flow | Foreign Exchange Contract | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets			5
Cash Flow | Foreign Exchange Contract | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets			1
Cash Flow | Foreign Exchange Contract | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities			(10)
Cash Flow | Foreign Exchange Contract | Net Investment | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities			$ (2)
Net Investment | Net Investment
Derivative [Line Items]
Notional Amount		1,169
Derivative, Fair Value, Net		43
Net Investment | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets		0
Net Investment | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets		43
Net Investment | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities		0
Net Investment | Net Investment | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities		$ 0

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) € in Millions, $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2020EUR (€)	Dec. 31, 2019EUR (€)	Nov. 30, 2019EUR (€)	Jul. 31, 2019USD ($)	Nov. 30, 2018EUR (€)
Foreign Exchange Contract
Notional amount	$ 7,612	$ 8,088
Designated as Hedging Instrument | Foreign Exchange Contract
Notional amount	824	1,113		€ 2,400		$ 1,000	€ 2,250
Derivative, fair value	(179)
Cash flow hedge gain (loss) to be reclassified within twelve months	6
Other Income	27
Designated as Hedging Instrument | Interest Rate Swap
Notional amount	750
Cash flow hedge gain (loss) to be reclassified within twelve months		$ 6
Notional amount terminated | €			€ 500		€ 600
Net Investment | Designated as Hedging Instrument
Notional amount	1,169
Accrued Expenses | Designated as Hedging Instrument | Interest Rate Swap
Pretax losses recorded in AOCI	$ 66

Derivative Instruments (Income

Derivative Instruments (Income Statement Location) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 7	$ 3	$ 11	$ 1
Foreign Exchange Contract | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	3	2	3	4
Foreign Exchange Contract | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	(3)	(6)	(12)	(10)
Net Investment | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 7	$ 7	$ 20	$ 7

Fair Value Measurements (Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 7,083	$ 4,337
Assets
Available-for-sale securities, current	78	88
Investments Fair Value Disclosure	7,382	4,817
Contingent consideration:
Total liabilities measured at fair value	611	478
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	7,083	4,337
Trading marketable securities	154	149
Assets
Investments Fair Value Disclosure	7,237	4,486
Deferred compensation arrangements	154	149
Contingent consideration:
Total liabilities measured at fair value	154	149
Fair Value, Inputs, Level 2
Assets
Available-for-sale securities, current	78	88
Investments Fair Value Disclosure	145	331
Contingent consideration:
Total liabilities measured at fair value	170	23
Fair Value, Inputs, Level 2 | Foreign currency exchange forward contracts
Assets
Derivative asset	67	226
Liabilities
Foreign currency exchange forward contracts	105	23
Fair Value, Inputs, Level 2 | Interest Rate Swap
Assets
Derivative asset	0	17
Liabilities
Foreign currency exchange forward contracts	65	0
Fair Value, Inputs, Level 2 | Corporate and asset-backed debt securities
Assets
Available-for-sale securities, current	37	32
Fair Value, Inputs, Level 2 | United States agency debt securities
Assets
Available-for-sale securities, current	6	2
Fair Value, Inputs, Level 2 | United States Treasury debt securities
Assets
Available-for-sale securities, current	34	49
Fair Value, Inputs, Level 2 | Certificates of deposit
Assets
Available-for-sale securities, current	1	5
Fair Value, Inputs, Level 3
Contingent consideration:
Beginning	306	117
Additions	5	298
Change in estimate	6	(10)
Settlements	(30)	(99)
Ending	287	306
Total liabilities measured at fair value	$ 287	$ 306

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Due in one year or less	$ 40	$ 50
Due after one year through three years	38	38
Fair Value, Inputs, Level 2 | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency exchange forward contracts	65	0
Fair Value, Inputs, Level 2 | Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency exchange forward contracts	$ 105	$ 23

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Gain on sale of marketable securities	$ 19	$ 36	$ 84	$ 109

Contingencies and Commitments_2

Contingencies and Commitments (Narrative) (Details) $ in Millions	Sep. 30, 2020USD ($)
Minimum
Loss Contingencies [Line Items]
Estimate of possible loss	$ 280
Maximum
Loss Contingencies [Line Items]
Estimate of possible loss	$ 515

Contingencies and Commitments -

Contingencies and Commitments - Leases (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets	$ 401		$ 401		$ 384
Lease liabilities, current	100		100		86
Lease liabilities, non-current	$ 310		$ 310		$ 301
Other information
Weighted-average remaining lease term	5 years 6 months		5 years 6 months		6 years 2 months 12 days
Weighted-average discount rate	2.87%		2.87%		3.34%
Operating lease cost	$ 27	$ 34	$ 94	$ 102

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ / shares in Units, $ in Millions	1 Months Ended				9 Months Ended
	Nov. 30, 2019USD ($)$ / shares	Nov. 30, 2019€ / shares	Oct. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions					$ 26	$ 446
Acquisitions, net of cash acquired					$ 26	$ 281
Mobius
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions			$ 360
Future milestone payments			$ 130
OrthoSpace, Ltd.
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions				$ 110
Future milestone payments				$ 110
Wright
Business Acquisition [Line Items]
Consideration transferred (in dollars per share) | $ / shares	$ 30.75
Acquisitions, net of cash acquired	$ 5,400
Par value of ordinary shares of acquiree (in EUR per share) | € / shares		€ 0.03

Acquisitions (Allocation Of The

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Goodwill		$ 9,128	$ 9,069
Mobius
Accounts receivable			3
Inventory			6
Other assets			2
Contingent consideration			(4)
Other liabilities			(10)
Goodwill			303
Purchase price, net of cash acquired			473
Weighted-average life of intangible assets	12 years
Mobius | Customer relationship
Intangible assets acquired			7
Mobius | Developed technology and patents
Intangible assets acquired			59
Mobius | In-process research and development
Intangible assets acquired			98
Mobius | Non-compete agreements
Intangible assets acquired			9
OrthoSpace, Ltd.
Accounts receivable			1
Inventory			1
Other assets			1
Contingent consideration			0
Other liabilities			(29)
Goodwill			114
Purchase price, net of cash acquired			208
Weighted-average life of intangible assets	18 years
OrthoSpace, Ltd. | Customer relationship
Intangible assets acquired			0
OrthoSpace, Ltd. | Developed technology and patents
Intangible assets acquired			120
OrthoSpace, Ltd. | In-process research and development
Intangible assets acquired			0
OrthoSpace, Ltd. | Non-compete agreements
Intangible assets acquired			$ 0

Acquisitions (Future Amortizati

Acquisitions (Future Amortization Expense) (Details) $ in Millions	Sep. 30, 2020USD ($)
Business Combinations [Abstract]
Remainder of 2020	$ 115
2021	446
2022	436
2023	421
2024	$ 390

Debt and Credit Facilities (Det

Debt and Credit Facilities (Details)	Apr. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020Rate	Sep. 30, 2020	Jan. 31, 2020USD ($)Rate	Dec. 31, 2019USD ($)
Amounts outstanding under commercial paper program			$ 0
Other Long-term Debt			19,000,000				$ 26,000,000
Total debt			13,127,000,000				11,090,000,000
Less current maturities of debt			1,119,000,000				859,000,000
Total long-term debt			12,008,000,000				10,231,000,000
Unamortized debt issuance costs			71,000,000				58,000,000
Available secured borrowing capacity			2,904,000,000				1,403,000,000
Fair value of senior unsecured notes			$ 14,366,000,000				11,910,000,000
Commercial Paper
Debt instrument, maturity			397 days
Commercial Paper | Maximum
Commercial paper			$ 1,500,000,000
Senior Unsecured Notes 4.375% due 2020
Stated interest rate | Rate				4.375%		4.375%
Maturity Date			Jan. 15, 2020
Unsecured Debt			$ 0				500,000,000
Debt instrument, repurchased face amount						$ 500,000,000
Senior Unsecured Notes Variable due 2020
Maturity Date			Nov. 30, 2020
Unsecured Debt			$ 351,000,000				333,000,000
Senior Unsecured Notes 2.625% due 2021
Stated interest rate | Rate				2.625%
Maturity Date			Mar. 15, 2021
Unsecured Debt			$ 750,000,000				749,000,000
Senior Unsecured Notes 1.125% due 2021
Stated interest rate | Rate				1.125%
Maturity Date			Nov. 30, 2023
Unsecured Debt			$ 640,000,000				609,000,000
Senior Unsecured Notes 3.375% due 2024
Stated interest rate | Rate				3.375%
Maturity Date			May 15, 2024
Unsecured Debt			$ 590,000,000				587,000,000
Senior Unsecured Notes, 0.250% Due 2024
Stated interest rate					0.25%
Maturity Date			Dec. 3, 2024
Unsecured Debt			$ 987,000,000				938,000,000
Senior Unsecured Notes, 1.150% Due 2025
Stated interest rate					1.15%
Maturity Date			Jun. 15, 2025
Unsecured Debt			$ 644,000,000				0
Proceeds from issuance of debt		$ 650,000,000
Redemption price of notes (as a percent)		101.00%
Senior Unsecured Notes 3.375% due 2025
Stated interest rate | Rate				3.375%
Maturity Date			Nov. 1, 2025
Unsecured Debt			$ 747,000,000				746,000,000
Senior Unsecured Notes 3.50% due 2026
Stated interest rate | Rate				3.50%
Maturity Date			Mar. 15, 2026
Unsecured Debt			$ 992,000,000				991,000,000
Senior Unsecured Notes 2.125% due 2027
Stated interest rate | Rate				2.125%
Maturity Date			Nov. 30, 2027
Unsecured Debt			$ 871,000,000				829,000,000
Senior Unsecured Notes 3.650% due 2028
Stated interest rate | Rate				3.65%
Maturity Date			Mar. 7, 2028
Unsecured Debt			$ 596,000,000				596,000,000
Senior Unsecured Notes, 0.750% Due 2029
Stated interest rate					0.75%
Maturity Date			Mar. 1, 2029
Unsecured Debt			$ 929,000,000				884,000,000
Senior Unsecured Notes, 1.950% Due 2030
Stated interest rate					1.95%
Maturity Date			Jun. 15, 2030
Unsecured Debt			$ 988,000,000				0
Proceeds from issuance of debt		$ 1,000,000,000
Senior Unsecured Notes 2.625% due 2030
Stated interest rate | Rate				2.625%
Maturity Date			Nov. 30, 2030
Unsecured Debt			$ 749,000,000				712,000,000
Senior Unsecured Notes, 1.000% Due 2031
Stated interest rate					1.00%
Maturity Date			Dec. 3, 2031
Unsecured Debt			$ 865,000,000				823,000,000
Senior Unsecured Notes 4.100% due 2043
Stated interest rate | Rate				4.10%
Maturity Date			Apr. 1, 2043
Unsecured Debt			$ 392,000,000				391,000,000
Senior Unsecured Notes 4.375% due 2044
Stated interest rate | Rate				4.375%
Maturity Date			May 15, 2044
Unsecured Debt			$ 395,000,000				395,000,000
Senior Unsecured Notes 4.625% due 2046
Stated interest rate | Rate				4.625%
Maturity Date			Mar. 15, 2046
Unsecured Debt			$ 981,000,000				981,000,000
Senior Unsecured Notes, 2.900% due 2050
Stated interest rate				2.90%	2.90%
Maturity Date			Jun. 15, 2050
Unsecured Debt			$ 641,000,000				$ 0
Proceeds from issuance of debt		$ 650,000,000
Revolving Credit Facility
Leverage ratio	4.5				3.5
Revolving Credit Facility | Credit Agreement
Debt instrument, maturity	364 days
Line of credit facility, maximum borrowing capacity	$ 1,500,000,000

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020Rate	Sep. 30, 2019Rate	Sep. 30, 2020Rate	Sep. 30, 2019Rate
Income Tax [Abstract]
Effective income tax rate reconciliation, percent	20.40%	19.80%	19.60%	16.50%

Segment Information (Sales And

Segment Information (Sales And Other Financial Information By Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Net sales	$ 3,737	$ 3,587	$ 10,089	$ 10,753
Segment operating income	859	628	1,474	1,769
Amortization of intangible assets	(114)	(116)	(342)	(352)
Recall-related matters	(2)	(49)	4	(179)
Orthopaedics
Segment Reporting Information [Line Items]
Net sales	1,317	1,262	3,433	3,785
MedSurg
Segment Reporting Information [Line Items]
Net sales	1,600	1,552	4,546	4,680
Neurotechnology and Spine
Segment Reporting Information [Line Items]
Net sales	820	773	2,110	2,288
Operating Segments
Segment Reporting Information [Line Items]
Net sales	3,737	3,587	10,089	10,753
Segment operating income	1,151	1,030	2,625	3,109
Operating Segments | Orthopaedics
Segment Reporting Information [Line Items]
Net sales	1,317	1,262	3,433	3,785
Segment operating income	472	437	1,027	1,322
Operating Segments | MedSurg
Segment Reporting Information [Line Items]
Net sales	1,600	1,552	4,546	4,680
Segment operating income	451	394	1,085	1,179
Operating Segments | Neurotechnology and Spine
Segment Reporting Information [Line Items]
Net sales	820	773	2,110	2,288
Segment operating income	228	199	513	608
Corporate and other
Segment Reporting Information [Line Items]
Segment operating income	(104)	(117)	(371)	(371)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisition and integration-related charges	(29)	(32)	(85)	(223)
Amortization of intangible assets	(114)	(116)	(342)	(352)
Restructuring-related and other charges	(29)	(48)	(292)	(146)
Medical device regulations	(14)	(15)	(60)	(34)
Recall-related matters	(2)	(49)	4	(179)
Regulatory and legal matters	$ 0	$ (25)	$ (5)	$ (35)

Asset Impairments (Details)

Asset Impairments (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Asset impairments	$ 189	$ 161	$ 2